Source: American journal of nephrology. Unidade: FM
Subjects: DIABETES MELLITUS, DOENÇAS CARDIOVASCULARES, NEFROPATIAS, URINA, MÉTODO DUPLO-CEGO, INSUFICIÊNCIA RENAL
ABNT
RUILOPE, Luis M et al. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. American journal of nephrology, v. 50, n. 5, p. 345-356, 2019Tradução . . Disponível em: https://doi.org/10.1159/000503712. Acesso em: 31 ago. 2024.APA
Ruilope, L. M., Agarwal, R., Anker, S. D., Bakris, G. L., Filippatos, G., Nowack, C., et al. (2019). Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. American journal of nephrology, 50( 5), 345-356. doi:10.1159/000503712NLM
Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Noronha I de L. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial [Internet]. American journal of nephrology. 2019 ; 50( 5): 345-356.[citado 2024 ago. 31 ] Available from: https://doi.org/10.1159/000503712Vancouver
Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Noronha I de L. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial [Internet]. American journal of nephrology. 2019 ; 50( 5): 345-356.[citado 2024 ago. 31 ] Available from: https://doi.org/10.1159/000503712